Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy

Creative Commons License

Tonelli A. R., Haserodt S., Aytekin M., Dweik R. A.

PULMONARY CIRCULATION, vol.3, no.1, pp.20-30, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 3 Issue: 1
  • Publication Date: 2013
  • Doi Number: 10.4103/2045-8932.109911
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.20-30
  • Erciyes University Affiliated: Yes


Nitric oxide (NO) is a diffusible gas with diverse roles in human physiology and disease. Significant progress in the understanding

of its biological effects has taken place in recent years. This has led to a better understanding of the pathobiology of pulmonary

hypertension (PH) and the development of new therapies. This article provides an overview of the NO physiology and its role

in the pathobiology of lung diseases, particularly PH. We also discuss current and emerging specific treatments that target NO

signaling pathways in PH.